9PT.F PLIANT THERA.INC.DL-0001
- Market cap
- EUR 43.3M
- P/E
- -
- P/B
- 0.34x
- ROE
- -57.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 9PT.F undervalued?
Graham numberThe Graham number of PLIANT THERA.INC.DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PLIANT THERA.INC.DL-0001 fundamental analysis
No fundamental analysis for PLIANT THERA.INC.DL-0001 yet.
PLIANT THERA.INC.DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PLIANT THERA.INC.DL-0001
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusin…
Full company profilePLIANT THERA.INC.DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PLIANT THERA.INC.DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 7.57M | 9.69M | 1.58M | 0.00 | 0.00 | 0.00 |
| Operating Income | -97.5M | -127M | -184M | -228M | -156M | -91.3M |
| EBITDA | - | -121M | -158M | -205M | -145M | -83.8M |
| Net Income | -97.3M | -123M | -161M | -210M | -149M | -84.8M |
| EPS | -2.70 | -2.52 | -2.69 | -3.46 | -2.43 | -1.37 |
| Balance Sheet | ||||||
| Total Assets | 221M | 351M | 512M | 397M | 225M | 190M |
| Total Liabilities | 22.2M | 37.3M | 38.6M | 92.9M | 44.0M | 43.0M |
| Shareholders' Equity | 199M | 313M | 474M | 304M | 181M | 147M |
| Cash & Short-term Investments | 51.7M | 33.7M | 63.2M | 71.2M | 45.4M | 24.9M |
| Cash Flow | ||||||
| Operating Cash Flow | -75.4M | -94.6M | -116M | -156M | -128M | -64.1M |
| Capital Expenditure | 1.95M | 1.76M | 921K | 3.85M | 374K | 0.00 |
| Free Cash Flow | -77.4M | -96.4M | -117M | -159M | -129M | -64.1M |
| Ratios | ||||||
| ROE | -48.9% | -39.4% | -34.1% | -69.2% | -82.4% | -57.7% |
| ROA | -44.0% | -35.2% | -31.5% | -53.0% | -66.3% | -44.7% |
| Net Profit Margin | -1,284.5% | -1,273.3% | -10,211.1% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PLIANT THERA.INC.DL-0001 dividends
PLIANT THERA.INC.DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns PLIANT THERA.INC.DL-0001
- Insiders 2.23%
- Institutions 77.65%
- Public & others 20.13%
- Shares outstanding 61.9M
- Free float 55.0M
PLIANT THERA.INC.DL-0001 company profile
- Company name
- PLIANT THERA.INC.DL-0001
- Ticker
- 9PT.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Fiscal year end
- December
- Address
- 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 481 6770
- Website
- pliantrx.com
About PLIANT THERA.INC.DL-0001
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
PLIANT THERA.INC.DL-0001 management
10- Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D.President, CEO & Director · born 1966
- Dr. Keith Lamont Cummings M.B.A., M.D.Chief Financial Officer · born 1977
- Ms. Minnie KuoChief Operating Officer · born 1981
- Dr. Rik Derynck Ph.D.Scientific Founder & Member of Scientific Advisory Board
- Mr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory Board
- Mr. Bill DeGrado Ph.D.Scientific Founder
- Mr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory Board
- Ms. Delphine Imbert Ph.D.Chief Technical Officer
- Mr. Christopher S. KeenanVice President of Investor Relations & Corporate Communications
- Ms. Lily CheungChief Human Resources Officer · born 1973